Victory Capital Management Inc. Has $5.89 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Victory Capital Management Inc. boosted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1,729.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 130,797 shares of the company's stock after purchasing an additional 123,647 shares during the period. Victory Capital Management Inc. owned 0.22% of Protagonist Therapeutics worth $5,886,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Protagonist Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company's stock worth $92,373,000 after purchasing an additional 39,055 shares in the last quarter. New York State Teachers Retirement System bought a new position in Protagonist Therapeutics in the third quarter valued at about $1,107,000. Seven Eight Capital LP boosted its holdings in Protagonist Therapeutics by 426.9% in the second quarter. Seven Eight Capital LP now owns 36,793 shares of the company's stock valued at $1,275,000 after acquiring an additional 29,810 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Protagonist Therapeutics by 9.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company's stock worth $7,079,000 after purchasing an additional 17,065 shares during the last quarter. Finally, Dark Forest Capital Management LP bought a new stake in shares of Protagonist Therapeutics during the second quarter worth approximately $2,112,000. Institutional investors own 98.63% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. TD Cowen upgraded Protagonist Therapeutics to a "strong-buy" rating in a report on Wednesday, September 25th. Truist Financial initiated coverage on shares of Protagonist Therapeutics in a report on Monday, September 9th. They set a "buy" rating and a $60.00 price objective for the company. StockNews.com upgraded shares of Protagonist Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a report on Tuesday. Finally, Wedbush restated an "outperform" rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Protagonist Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $53.57.

Protagonist Therapeutics Stock Up 11.5 %

Shares of NASDAQ:PTGX traded up $4.81 during midday trading on Friday, reaching $46.46. 1,322,201 shares of the company were exchanged, compared to its average volume of 733,287. The firm has a market cap of $2.77 billion, a PE ratio of 17.47 and a beta of 2.17. Protagonist Therapeutics, Inc. has a fifty-two week low of $16.80 and a fifty-two week high of $48.89. The stock has a fifty day simple moving average of $45.25 and a two-hundred day simple moving average of $39.16.

Insider Buying and Selling at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 1,906 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total value of $78,107.88. Following the completion of the transaction, the insider now owns 46,444 shares in the company, valued at $1,903,275.12. This trade represents a 3.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the sale, the chief financial officer now directly owns 34,960 shares in the company, valued at approximately $1,555,370.40. This represents a 28.89 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,109 shares of company stock worth $1,069,999. Corporate insiders own 5.40% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.